AR119173A1 - Agonistas del receptor del péptido-1 similar al glucagón - Google Patents
Agonistas del receptor del péptido-1 similar al glucagónInfo
- Publication number
- AR119173A1 AR119173A1 ARP200101699A ARP200101699A AR119173A1 AR 119173 A1 AR119173 A1 AR 119173A1 AR P200101699 A ARP200101699 A AR P200101699A AR P200101699 A ARP200101699 A AR P200101699A AR 119173 A1 AR119173 A1 AR 119173A1
- Authority
- AR
- Argentina
- Prior art keywords
- glucagon
- peptide
- receptor agonists
- compound
- formula
- Prior art date
Links
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En una modalidad, la presente proporciona un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, y métodos para usar este compuesto en el tratamiento de la diabetes mellitus tipo II. Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ es H o F; R² es H o F; y R³ es H o CH₃; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868117P | 2019-06-28 | 2019-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119173A1 true AR119173A1 (es) | 2021-12-01 |
Family
ID=80781601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101699A AR119173A1 (es) | 2019-06-28 | 2020-06-17 | Agonistas del receptor del péptido-1 similar al glucagón |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR119173A1 (es) |
| MA (1) | MA56391B1 (es) |
-
2020
- 2020-06-17 AR ARP200101699A patent/AR119173A1/es unknown
- 2020-06-19 MA MA56391A patent/MA56391B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA56391B1 (fr) | 2023-11-30 |
| MA56391A (fr) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000273A (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| CL2021000158A1 (es) | Compuestos coagonistas de gip/glp1 | |
| ECSP21000990A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| AR045173A1 (es) | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| PE20211595A1 (es) | Compuestos de 2,6-diaminopiridina | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| AR094990A1 (es) | Derivados de amida y su uso para el tratamiento de infección por vih | |
| AR099399A1 (es) | Compuesto heterocíclico | |
| CO2021016870A2 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| AR092202A1 (es) | Derivados de azabencimidazoltetrahidrofurano utiles como activadores de la proteina cinasa activada por amp | |
| AR040780A1 (es) | Compuesto derivado de azuleno y composicion farmaceutica que lo contiene | |
| PE20212070A1 (es) | Moduladores de trex1 | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| UY38958A (es) | Agonista del receptor glp-1 y uso de este | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| AR119173A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| AR114467A1 (es) | Moduladores alostéricos positivos del receptor de dopamina d1 | |
| DOP2018000134A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| AR125905A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| AR115382A1 (es) | Compuestos de ciclopentano | |
| ECSP066639A (es) | Moduladores del receptor activado por el proliferador selectivo de peroxisoma |